Uses of Pivalo 4: - High cholesterol Hypercholesterolaemia, Hyperlipidaemias, Mixed dyslipidaemia, Cardiovascular disease, Patients with a known hypersensitivity to any component of this products. Pitavastatin is contraindicated in patients with active liver disease , which may include unexplained persistent elevations of hepatic transaminase levels.

How to use Pitavastatin: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Pitavastatin may be taken with or without food, but it is better to take it at a fixed time. Administration: May be taken with or without food. Adult Dose: Oral Hypercholesterolemia Adult: 2 mg once daily. May increase to 4 mg qDay if necessary. Hepatic Impairment Contraindicated in active liver disease or unexplained transaminase elevations Child Dose: Safety and efficacy not established Renal Dose: Renal impairment: Moderate to severe (CrCl 15-60 mL/min, not on haemodialysis) and ESRD (on haemodialysis): Initial: 1 mg once daily. Max: 2 mg once daily.

Increased bioavailability w/ erythromycin and rifampicin. Increased risk of myopathy/rhabdomyolysis w/ gemfibrozil, colchicine, niacin and other fibrates. Potentially Fatal: Ciclosporin significantly increases pitavastatin exposure.

Patients with a known hypersensitivity to any component of this products. Pitavastatin is contraindicated in patients with active liver disease , which may include unexplained persistent elevations of hepatic transaminase levels.

Common - Constipation - Muscle pain Liver enzyme abnormalities, myalgia, muscle spasm, back pain, diarrhoea, constipation, pain in extremities, arthralgia, headache, dizziness, influenza, nasopharyngitis, abdominal discomfort, abdominal pain, dyspepsia, nausea, asthenia, malaise, fatigue, hepatitis, jaundice, hypoaesthesia, insomnia, depression, interstitial lung disease, erectile dysfunction, cognitive impairment (e.g. memory loss and impairment, confusion, forgetfulness, amnesia). Potentially Fatal: Myopathy and rhabdomyolysis w/ acute renal failure secondary to myoglobinuria; hepatic failure.

Precaution: Patient w/ predisposing factors for myopathy; alcoholism. Renal impairment. Monitoring Parameters Monitor lipid panel (total cholesterol, HDL, LDL, triglycerides), hepatic transaminase levels; creatine phosphokinase (CPK). Lactation: Contraindicated

HMG-CoA reductase inhibitor, inhibits rate-limiting step in cholesterol biosynthesis by competitively inhibiting HMG-CoA reductase